JP2020508985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508985A5 JP2020508985A5 JP2019543376A JP2019543376A JP2020508985A5 JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5 JP 2019543376 A JP2019543376 A JP 2019543376A JP 2019543376 A JP2019543376 A JP 2019543376A JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- dendrimer
- formula
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000412 dendrimer Substances 0.000 claims description 90
- 229920000736 dendritic polymer Polymers 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 description 29
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461983P | 2017-02-22 | 2017-02-22 | |
| US62/461,983 | 2017-02-22 | ||
| US201762488151P | 2017-04-21 | 2017-04-21 | |
| US62/488,151 | 2017-04-21 | ||
| US201762591823P | 2017-11-29 | 2017-11-29 | |
| US62/591,823 | 2017-11-29 | ||
| PCT/EP2018/054420 WO2018154004A1 (en) | 2017-02-22 | 2018-02-22 | Therapeutic dendrimers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508985A JP2020508985A (ja) | 2020-03-26 |
| JP2020508985A5 true JP2020508985A5 (OSRAM) | 2021-03-11 |
| JP7074761B2 JP7074761B2 (ja) | 2022-05-24 |
Family
ID=61386833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543376A Active JP7074761B2 (ja) | 2017-02-22 | 2018-02-22 | 治療用デンドリマー |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10314920B2 (OSRAM) |
| EP (1) | EP3585441A1 (OSRAM) |
| JP (1) | JP7074761B2 (OSRAM) |
| KR (2) | KR102544033B1 (OSRAM) |
| CN (2) | CN110312531A (OSRAM) |
| AU (1) | AU2018223149B2 (OSRAM) |
| BR (1) | BR112019016409A2 (OSRAM) |
| CA (1) | CA3053069A1 (OSRAM) |
| CL (1) | CL2019002240A1 (OSRAM) |
| CO (1) | CO2019009722A2 (OSRAM) |
| CR (1) | CR20190361A (OSRAM) |
| DO (1) | DOP2019000204A (OSRAM) |
| EC (1) | ECSP19056271A (OSRAM) |
| IL (1) | IL268648B (OSRAM) |
| JO (1) | JOP20190191A1 (OSRAM) |
| MX (1) | MX2019009442A (OSRAM) |
| NI (1) | NI201900088A (OSRAM) |
| PE (1) | PE20191660A1 (OSRAM) |
| PH (1) | PH12019501896A1 (OSRAM) |
| SG (1) | SG11201907334QA (OSRAM) |
| TW (1) | TWI773730B (OSRAM) |
| UA (1) | UA125655C2 (OSRAM) |
| WO (1) | WO2018154004A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI856967B (zh) | 2018-08-17 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| US20220023290A1 (en) * | 2018-11-20 | 2022-01-27 | Starpharma Pty Ltd | Therapeutic dendrimer |
| CN113825397B (zh) | 2019-05-07 | 2023-10-27 | 赛丹思科大学 | 用于布撒生物材料的机件 |
| JP2022549680A (ja) * | 2019-09-26 | 2022-11-28 | スターファーマ ピーティーワイ エルティーディー | 治療用デンドリマー |
| WO2021113651A2 (en) * | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| TW202206106A (zh) * | 2020-04-24 | 2022-02-16 | 大陸商上海森輝醫藥有限公司 | 一類載藥的大分子及其製備方法 |
| CN116075322A (zh) | 2020-04-24 | 2023-05-05 | 阿什瓦塔治疗股份有限公司 | 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法 |
| EP4180422A4 (en) * | 2020-07-10 | 2024-01-24 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | SULFONYL BENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PROCESS THEREOF AND USE THEREOF |
| CN116133693A (zh) | 2020-08-25 | 2023-05-16 | 上海森辉医药有限公司 | 载药的大分子及其制备方法 |
| WO2022040761A1 (en) * | 2020-08-31 | 2022-03-03 | Starpharma Pty Ltd | Dendrimer-drug conjugate |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4410688A (en) * | 1981-04-29 | 1983-10-18 | Allied Corporation | Macromolecular highly branched homogeneous compound |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| CA2626865C (en) * | 2005-10-25 | 2014-12-30 | Starpharma Pty Limited | Macromolecular compounds having controlled stoichiometry |
| CA2636599C (en) * | 2006-01-20 | 2014-07-15 | Starpharma Pty Limited | Modified macromolecule |
| PL2052011T3 (pl) * | 2006-08-11 | 2021-03-08 | Starpharma Pty Limited | Nakierowany środek terapeutyczny będący dendrymerem polilizynowym |
| US9127130B2 (en) * | 2006-08-11 | 2015-09-08 | Starpharma Pty Ltd. | Polylysine dendrimer contrast agent |
| JP5366817B2 (ja) | 2006-11-15 | 2013-12-11 | ジェネンテック， インコーポレイテッド | アリールスルホンアミド化合物 |
| US9283302B2 (en) | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US8216549B2 (en) * | 2008-07-25 | 2012-07-10 | National Health Research Institutes | Method for making a ligand-quantum dot conjugate |
| RU2497822C2 (ru) | 2008-12-05 | 2013-11-10 | Эббви Инк. | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UY32668A (es) | 2009-05-26 | 2010-12-31 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| WO2011046842A1 (en) * | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| IN2014DN00101A (OSRAM) * | 2011-06-06 | 2015-05-15 | Starpharma Pty Ltd | |
| US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
| US10730999B2 (en) * | 2014-06-06 | 2020-08-04 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| TWI856967B (zh) * | 2018-08-17 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
-
2017
- 2017-06-16 JO JOP/2019/0191A patent/JOP20190191A1/ar unknown
-
2018
- 2018-02-12 TW TW107105033A patent/TWI773730B/zh active
- 2018-02-20 US US15/899,892 patent/US10314920B2/en active Active
- 2018-02-22 MX MX2019009442A patent/MX2019009442A/es unknown
- 2018-02-22 UA UAA201909735A patent/UA125655C2/uk unknown
- 2018-02-22 WO PCT/EP2018/054420 patent/WO2018154004A1/en not_active Ceased
- 2018-02-22 PE PE2019001564A patent/PE20191660A1/es unknown
- 2018-02-22 CN CN201880012429.9A patent/CN110312531A/zh active Pending
- 2018-02-22 AU AU2018223149A patent/AU2018223149B2/en not_active Ceased
- 2018-02-22 SG SG11201907334QA patent/SG11201907334QA/en unknown
- 2018-02-22 JP JP2019543376A patent/JP7074761B2/ja active Active
- 2018-02-22 CA CA3053069A patent/CA3053069A1/en active Pending
- 2018-02-22 CR CR20190361A patent/CR20190361A/es unknown
- 2018-02-22 KR KR1020197027415A patent/KR102544033B1/ko active Active
- 2018-02-22 KR KR1020237019533A patent/KR20230093346A/ko not_active Abandoned
- 2018-02-22 EP EP18707681.5A patent/EP3585441A1/en active Pending
- 2018-02-22 CN CN202311534590.1A patent/CN117582521A/zh active Pending
- 2018-02-22 BR BR112019016409A patent/BR112019016409A2/pt active Search and Examination
-
2019
- 2019-04-05 US US16/376,419 patent/US10888624B2/en active Active
- 2019-08-06 EC ECSENADI201956271A patent/ECSP19056271A/es unknown
- 2019-08-08 CL CL2019002240A patent/CL2019002240A1/es unknown
- 2019-08-08 DO DO2019000204A patent/DOP2019000204A/es unknown
- 2019-08-12 IL IL268648A patent/IL268648B/en unknown
- 2019-08-15 PH PH12019501896A patent/PH12019501896A1/en unknown
- 2019-08-20 NI NI201900088A patent/NI201900088A/es unknown
- 2019-09-09 CO CONC2019/0009722A patent/CO2019009722A2/es unknown
-
2020
- 2020-11-11 US US17/095,043 patent/US11717574B2/en active Active
-
2023
- 2023-06-14 US US18/334,672 patent/US20240115716A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508985A5 (OSRAM) | ||
| KR100559068B1 (ko) | 캄프토테신 유도체, 이의 중합체성 복합체, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물 | |
| JP2008536807A5 (OSRAM) | ||
| JP2008528671A5 (OSRAM) | ||
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| CA3025931A1 (en) | Antibody drug conjugates having derivatives of amatoxin as the drug | |
| RU2011118055A (ru) | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств | |
| JP2008542399A5 (OSRAM) | ||
| KR20210034011A (ko) | 치료 덴드리머 | |
| US6376617B1 (en) | Bioactive derivatives of camptothecin | |
| RU2130941C1 (ru) | Трехъядерные катионные комплексы платины, проявляющие противоопухолевую активность, способ их получения и фармацевтические композиции, содержащие эти комплексы | |
| CA2396702A1 (en) | N,o-amidomalonate platinum complexes | |
| JP7506659B2 (ja) | 癌を処置する方法に用いられるコンジュゲート | |
| WO2014084378A1 (ja) | 環状ｒｇｄ配列含有ペプチドを含む抗癌剤 | |
| WO2005079396A2 (en) | O,o'-amidomalonate and n,o-amidomalonate platinum complexes | |
| JP2008504235A5 (OSRAM) | ||
| EP2737896B1 (en) | Umirolimus micelle for the treating cancer | |
| CA3126574C (en) | Cd44 targeted multi-arm conjugate | |
| TW201004631A (en) | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | |
| KR102138415B1 (ko) | 신규 peg 유도체 | |
| CA2542007A1 (en) | Protein tyrosine kinase inhibitors | |
| HRP20100301T1 (hr) | Ciklopeptidni derivati sa anti-integrinskom aktivnošću | |
| US20030092608A1 (en) | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| CN108697696B (zh) | 抗肿瘤剂 | |
| JP2021527123A (ja) | 環状ペプチド化合物およびその使用方法 |